Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 2Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Endocrine 2

Conditions

Neuroendocrine Tumors 71Pituitary Neoplasms 47Thyroid Cancer, Papillary 28Multiple Endocrine Neoplasia Type 1 21Carcinoma, Neuroendocrine 21Pheochromocytoma 18Paraganglioma 14Thyroid Neoplasms 13Carcinoid Tumor 13Neoplasm Metastasis 12Differentiated Thyroid Cancer 12Adrenocortical Carcinoma 11Neoplasms 10Thyroid Carcinoma, Anaplastic 9Pancreatic Neoplasms 8Insulinoma 8Adrenal Gland Neoplasms 8Pituitary Diseases 6Lung Neoplasms 6Hyperaldosteronism 6Gastro-enteropancreatic neuroendocrine tumor 6Acromegaly 6Stomach Neoplasms 5Prostatic Neoplasms 5Prolactinoma 5Head and Neck Neoplasms 5Carcinoma, Hepatocellular 5Breast Neoplasms 5Adrenocortical Adenoma 5Adenoma, Islet Cell 5

Interventions

candesartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Essential Hypertension × Endocrine × Clear all
NCT06090617 2024-03-19

WHYSKI

University Hospital Padova

Unknown
35 enrolled
Endocrine

Essential Hypertension, Hyperaldosteronism, Hypertension, Adrenocortical Adenoma

NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡